Outlook Therapeutics, Inc. Stockholders Equity

• Outlook Therapeutics, Inc. showed an increase of +56.0% in Stockholders Equity from 2024 to 2025.
• This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2025.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: -$37.86 million | Q2 2016: $1.56 million | Q4 2016: -$21.83 million | Q1 2017: -$26.85 million | Q2 2017: -$28.94 million | Q4 2017: -$25.09 million | Q1 2018: -$33.57 million | Q2 2018: -$13.20 million | Q4 2018: -$26.35 million | Q1 2019: -$28.09 million | Q2 2019: -$6.56 million | Q4 2019: -$30.93 million | Q1 2020: -$20.52 million | Q2 2020: $10.97 million | Q4 2020: -$10.47 million | Q1 2021: $20.65 million | Q2 2021: $12.75 million | Q4 2021: $48.82 million | Q1 2022: $35.96 million | Q2 2022: $20.08 million | Q4 2022: $15.76 million | Q1 2023: $10.49 million | Q2 2023: -$5.50 million | Q4 2023: -$24.34 million | Q1 2024: -$134.24 million | Q2 2024: -$83.67 million | Q3 2024: -$73.08 million | Q4 2024: -$50.29 million | Q1 2025: -$32.46 million | Q2 2025: -$37.19 million | Q3 2025: -$32.19 million | Q4 2025: -$38.55 million.
• Over the full 11 years of available data (2015 to 2025), Outlook Therapeutics, Inc.'s Stockholders Equity has grown by 40.6%.
• Historical annual values: Fiscal year 2025: -$32.19 million | Fiscal year 2024: -$73.08 million | Fiscal year 2023: -$14.44 million | Fiscal year 2022: $8.74 million | Fiscal year 2021: $4.61 million | Fiscal year 2020: $2.83 million | Fiscal year 2019: -$16.13 million | Fiscal year 2018: -$25.54 million | Fiscal year 2017: -$33.65 million | Fiscal year 2016: -$5.17 million | Fiscal year 2015: -$54.22 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026